By Lina carolina 
The persistent challenge of pancreatic cancer, a disease that has largely resisted the revolutionary advances of cancer immunotherapy, may soon face a formidable new adversary. Researchers at the University of Chicago have unveiled an innovative therapeutic strategy that harnesses the power of engineered probiotic bacteria to deliver potent immune-stimulating agents directly to the tumor site, potentially overcoming the notoriously hostile tumor microenvironment that has long hampered treatment efficacy.
For years, oncologists have celebrated the successes of immunotherapies that unleash the body’s own immune system to target and destroy cancer cells. However, pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, has remained an outlier. Its characteristic "cold" tumor microenvironment, densely packed with immunosuppressive cells and lacking crucial immune infiltrates, acts as a formidable shield, preventing T cells and other immune warriors from mounting a successful assault. This stark contrast has made pancreatic cancer one of the deadliest cancers, with a five-year survival rate hovering around 11%, according to the American Cancer Society. The development of effective treatment strategies for this aggressive malignancy has been a critical unmet medical need, a sentiment echoed by leading researchers in the field.
"A big unmet medical need has been pancreatic cancer, and so that was going to be our mountain to climb," stated Dr. Ralph Weichselbaum, the Daniel K. Ludwig Distinguished Service Professor and Chair of Radiation and Cellular Oncology at the University of Chicago, underscoring the significance of this research endeavor.
The groundbreaking approach, detailed in a recent publication in the esteemed journal Science Advances, centers on BifidoSumIL-2, a genetically modified strain of Bifidobacterium longum. This common gut bacterium, a well-established probiotic with a favorable safety profile and already recognized for its presence in everyday foods like yogurt, has been repurposed as a sophisticated delivery vehicle. The engineered bacteria are designed to selectively colonize the low-oxygen environments characteristic of solid tumors, including pancreatic tumors, and, upon arrival, to release a modified version of interleukin-2 (IL-2).
IL-2 is a critical cytokine that plays a pivotal role in immune system function, particularly in activating T cells, the primary effectors of anti-cancer immunity. However, traditional systemic administration of IL-2 often leads to severe side effects due to its broad activation of immune cells, some of which can paradoxically dampen the anti-tumor response by stimulating regulatory T cells (Tregs). The University of Chicago team circumvented these limitations by developing SumIL-2, a precisely engineered variant of IL-2. This modified cytokine is designed to preferentially activate cancer-fighting CD8+ T cells while minimizing the activation of immunosuppressive Tregs.
The "Bugs as Drugs" Revolution: A Targeted Delivery System
The strategic placement of SumIL-2 within Bifidobacterium longum is the linchpin of this novel therapy. This ingenious design ensures that the potent immune-stimulating molecule is concentrated directly within the tumor mass, thereby maximizing its therapeutic impact while minimizing systemic exposure and the associated toxicities. This represents a significant advancement in the burgeoning field of "bugs as drugs," a paradigm shift that leverages the unique biological properties of microorganisms for therapeutic purposes.
The inherent tropism of Bifidobacterium for hypoxic tumor environments is a key factor in its efficacy. As an obligate anaerobe, B. longum thrives in oxygen-depleted conditions. Solid tumors, with their rapidly growing cell populations and inefficient vasculature, often create such oxygen-poor niches. In contrast, healthy tissues generally maintain higher oxygen levels, making them less hospitable for these engineered bacteria. When administered systemically, the bacteria are thus cleared from most healthy tissues, while preferentially accumulating and proliferating within the tumor.
"Bifidobacterium is an obligate anaerobe, so it doesn’t grow in the presence of oxygen," explained Dr. Mark Mimee, Assistant Professor of Microbiology at the University of Chicago, who was instrumental in the engineering of the bacterium. "When the bacteria are injected systemically, they are cleared from healthy tissues with abundant oxygen. Inside the low-oxygen regions of tumors, however, they can become active." This selective accumulation effectively transforms the bacteria into microscopic, tumor-localized drug factories.
The development of this sophisticated therapeutic required a deeply interdisciplinary collaboration, bringing together expertise from microbiology, synthetic biology, oncology, and immunology. "This was a highly interdisciplinary effort," Dr. Mimee emphasized. "We had to bring together people who understand bacteria, people who understand tumors, and people who understand the immune system to make something like this possible."
Preclinical Promise: Slowing Tumor Growth and Enhancing Existing Therapies
In rigorous preclinical studies conducted in animal models, BifidoSumIL-2 demonstrated a remarkable ability to slow the growth of pancreatic tumors. The therapy achieved this by selectively activating cancer-fighting T cells within the tumor microenvironment. Crucially, the researchers observed that the anti-tumor effects of BifidoSumIL-2 were significantly amplified when combined with conventional cancer treatments.
When BifidoSumIL-2 was administered alongside chemotherapy, radiotherapy, or existing immunotherapies (such as anti-PD-L1 agents), the results were even more pronounced. These combination regimens led to superior tumor control and extended survival compared to the individual treatments alone. This synergistic potential is particularly encouraging, suggesting that BifidoSumIL-2 could serve as a powerful adjuvant therapy, revitalizing the effectiveness of established treatments for pancreatic cancer.
"This combination potential is one of the study’s most important findings; BifidoSumIL-2 not only works by itself — it works with radiotherapy, chemotherapy, and immunotherapy," Dr. Weichselbaum reiterated, highlighting the versatility of the engineered probiotic.
The study’s findings indicate that BifidoSumIL-2 not only stimulates immune activity but also actively remodels the tumor microenvironment in a favorable direction. It was observed to increase the infiltration and activity of CD8+ T cells, the key cellular players in eradicating cancer cells. This reshaping of the tumor’s immune landscape is critical for overcoming the inherent resistance of pancreatic tumors to immunotherapy.
Challenges and Future Directions: Bridging the Gap to Human Trials
Despite the compelling preclinical data, the journey from laboratory discovery to clinical application involves several critical steps. BifidoSumIL-2 has not yet been tested in human subjects. Future research will be essential to thoroughly evaluate its long-term safety profile in humans, assess the potential for any off-target effects outside the intended tumor, and determine the duration and durability of the induced immune response.
Furthermore, the researchers are exploring the feasibility of alternative delivery methods, such as oral administration, which could offer greater convenience for patients. They also aim to investigate the compatibility of this bacterial therapy with emerging pancreatic cancer treatments, including targeted therapies aimed at specific genetic mutations like KRAS, which are prevalent in pancreatic tumors.
"Engineering Bifidobacterium was not simple," Dr. Mimee acknowledged, pointing to the inherent difficulties. "Bifidobacterium is not the easiest organism to work with. It’s anaerobic, it grows slowly, and the genetic tools for manipulating it are much more limited compared to model bacteria like E. coli. A lot of the work was just figuring out how to reliably engineer it." This underscores the significant scientific and technical hurdles overcome by the UChicago team.
Broader Implications: A New Frontier in Cancer Treatment
The development of BifidoSumIL-2 is a testament to the rapidly advancing field of synthetic biology and its potential to revolutionize medicine. The "bugs as drugs" approach represents a promising frontier, offering a way to deliver highly potent therapies with unprecedented precision, thereby enhancing efficacy and mitigating toxicity. This strategy holds the potential to be applied to a wide range of cancers that are currently difficult to treat.
The University of Chicago Medicine and its Biological Sciences Division are committed to remaining at the forefront of cancer care and research. The upcoming opening of the AbbVie Foundation Cancer Pavilion in April 2027, Chicago’s first freestanding cancer pavilion, signifies a substantial investment in advanced diagnostics, innovative treatments, and translational discoveries, further solidifying the institution’s role in combating complex diseases like pancreatic cancer.
The study, titled "Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy," received crucial support from the Ludwig Foundation and the National Institutes of Health. The collaborative effort involved a multidisciplinary team including Jaehyun Lee, Kaiting Yang, Christina Nowicki, Wei Liu, Emile Naccasha, and Hua Liang from the University of Chicago; Zhichen Sun from the University of Texas Southwestern, Dallas; and Yang-Xin Fu from Tsinghua University, Beijing, China, illustrating the global nature of cutting-edge scientific inquiry. This research marks a significant step forward in the quest for more effective treatments for one of the most challenging cancers, offering a beacon of hope for patients and a glimpse into the future of precision oncology.
